$ARIA News Six stocks to watch 3:27 p.m. Feb. 26, 2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 15, 2014 at 8:55 AM

$ARIA News

Six stocks to watch 3:27 p.m. Feb. 26, 2014 - The Trading Deck
6 stocks to watch 3:34 p.m. Feb. 12, 2014 - The Trading Deck
Ariad falls after wild ride upward, while Care.com holds on to its gains 9:02 p.m. Jan. 27, 2014 - Russ Britt
Apple green ahead of earnings; Caterpillar tops gainers 3:42 p.m. Jan. 27, 2014 - Sue Chang
Ariad shares jump nearly 30% on rumors of Big Pharma takeover 1:43 p.m. Jan. 24, 2014 - Russ Britt
5 charts to watch 3:52 p.m. Jan. 15, 2014 - The Trading Deck
Apple closes lower; B. of A. rises on analyst call 4:15 p.m. Jan. 2, 2014 - Wallace Witkowski
Apple gains on China Mobile deal; homebuilders rally 3:33 p.m. Dec. 23, 2013 - Wallace Witkowski
Suspension is lifted for Ariad's leukemia drug 6:33 a.m. Dec. 23, 2013 - MarketWatch.com
J.C. Penney and more of the year's most profitable shorts 3:23 p.m. Dec. 9, 2013 - blogs.marketwatch.com
Hewlett-Packard, a cyclical green light and why silver is in trouble 8:50 a.m. Nov. 26, 2013 - Shawn Langlois
Ariad takes another pounding after leukemia treatment is pulled 12:14 p.m. Oct. 31, 2013 - Russ Britt
H-P has best day in four months on upbeat outlook 3:34 p.m. Oct. 9, 2013 - Sue Chang
Ariad plummets 70% after drug test patients have serious clotting issues 10:38 a.m. Oct. 9, 2013 - Russ Britt
FDA places partial hold on Ariad's Iclusig trials 7:16 a.m. Oct. 9, 2013 - MarketWatch.com
Dan Loeb makes bet on Disney 7:06 p.m. Aug. 14, 2013 - David Benoit
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
SAC Capital Advisors likes this pharma stock 3:24 p.m. April 18, 2013 - Insider Monkey
Ariad Pharma up 6% to $20.09 10:35 a.m. Dec. 17, 2012 - Steve Gelsi
FDA OKs Iclusig to treat rare types of leukemia 1:06 p.m. Dec. 14, 2012 - MarketWatch.com

'Mad Money' Lightning Round: A Group to Avoid 6:00 a.m. Nov. 14, 2014 - TheStreet.com
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14) 3:40 a.m. Nov. 14, 2014 - Seeking Alpha
10-Q: ARIAD PHARMACEUTICALS INC 4:53 p.m. Nov. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals 8:58 a.m. Nov. 6, 2014 - benzinga.com
Ariad Pharmaceuticals' (ARIA) CEO Harvey Berger on Q3 2014 Results - Earnings Call Transcript 12:47 p.m. Nov. 5, 2014 - Seeking Alpha
Ariad updates guidance after Q3 results 9:49 a.m. Nov. 5, 2014 - Seeking Alpha
ARIAD Pharmaceuticals (ARIA) Q3 2014 Results - Earnings Call Webcast 8:25 a.m. Nov. 5, 2014 - Seeking Alpha
Notable earnings before Wednesday’s open 5:30 p.m. Nov. 4, 2014 - Seeking Alpha
Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog 5:00 p.m. Nov. 4, 2014 - Zacks.com
CHMP says Iclusig OK to use as is, advises revised label 10:26 a.m. Oct. 24, 2014 - Seeking Alpha
Biggest Movers in Healthcare Stocks Now – NPSP ARIA ANAC CLDX 8:30 a.m. Oct. 20, 2014 - InvestorPlace.com
ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today 9:45 a.m. Oct. 16, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – ARIA CLVS HZNP CBPO 1:00 p.m. Oct. 15, 2014 - InvestorPlace.com
ARIAD's Iclusig Gains Positive Recommendation from PRAC - Analyst Blog 5:05 p.m. Oct. 14, 2014 - Zacks.com
Amgen's Blinatumomab Gets Priority Review in the U.S. - Analyst Blog 5:55 p.m. Oct. 13, 2014 - Zacks.com
EMA's PRAC backs Iclusig 9:21 a.m. Oct. 10, 2014 - Seeking Alpha
ARIAD Gets Breakthrough Therapy Designation for AP26113 - Analyst Blog 5:49 p.m. Oct. 6, 2014 - Zacks.com
Ariad restructures license agreement with Bellicum 9:30 a.m. Oct. 6, 2014 - Seeking Alpha
Wayfair Rises, Westport Innovations Cuts Forecast 8:30 a.m. Oct. 6, 2014 - FOXBusiness
ARIAD Pharmaceuticals' All-In Bet On Europe 11:18 a.m. Oct. 5, 2014 - Seeking Alpha

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting 9:44 a.m. Nov. 6, 2014 - BusinessWire - BZX
ARIAD Reports Third Quarter 2014 Financial Results and Development Progress 7:36 a.m. Nov. 5, 2014 - BusinessWire - BZX
ARIAD to Present at the Stifel 2014 Healthcare Conference 7:35 a.m. Nov. 4, 2014 - BusinessWire - BZX
ARIAD Announces Adoption of Final Opinion for Iclusig by Committee for Medicinal Products for Human Use in Europe 6:35 a.m. Oct. 24, 2014 - BusinessWire - BZX
Insider Trading Alerts for Micron, CSX, Ariad Pharmaceuticals, IBM, SinoCoking Coal and Coke Chemical, and MannKind 7:55 a.m. Oct. 21, 2014 - PR Newswire - PRF
Insider Trading Research for Halliburton, Ariad Pharmaceuticals, KeyCorp, GoPro, MannKind, and Plug Power 7:45 a.m. Oct. 20, 2014 - PR Newswire - PRF
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Third Quarter 2014 Financial Results 6:35 a.m. Oct. 15, 2014 - BusinessWire - BZX
ARIAD Announces Recommendation for Iclusig by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency 6:44 a.m. Oct. 10, 2014 - BusinessWire - BZX
ARIAD and Bellicum Announce Revised License Agreement for ARIAD’s Cell-Signaling Technology 6:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
ARIAD’s AP26113 Receives FDA Breakthrough Therapy Designation For ALK+ Non-Small Cell Lung Cancer Resistant to Crizotinib 6:35 a.m. Oct. 2, 2014 - BusinessWire - BZX
ARIAD Presents Updated Clinical Data on AP26113 in Patients with ALK+ Non-Small Cell Lung Cancer 6:35 a.m. Sept. 29, 2014 - BusinessWire - BZX
INNATE PHARMA APPOINTS PIERRE DODION AS CHIEF MEDICAL OFFICER AND MEMBER OF THE EXECUTIVE COMMITTEE 11:41 a.m. Sept. 16, 2014 - GlobeNewswire
Technical Data on Biotech Stocks - ARIAD Pharma, Tekmira Pharma, Arrowhead Research, Celgene, and Amgen 7:55 a.m. Sept. 4, 2014 - PR Newswire - PRF
Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 12:19 p.m. Aug. 19, 2014 - PR Newswire - PRF
ARIAD Reports Second Quarter 2014 Financial Results and Development Progress 10:34 p.m. Aug. 6, 2014 - BusinessWire - BZX
ARIAD Announces Commercial Agreement for Iclusig (Ponatinib) in Israel 6:36 a.m. Aug. 5, 2014 - BusinessWire - BZX
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 8:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
ARIAD to Webcast Conference Call on Second Quarter 2014 Financial Results 6:35 a.m. July 16, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

WhiteHorse Set to Redeem Its 2028 Notes Completely

WhiteHorse Finance Divests Its 7.875% Notes Well, WhiteHorse Finance is making some moves, folks. They're planning to redeem their 7.875% notes due in 2028, totaling a cool $34.5 million. This ain't just pocket change, especially with the way markets have been bobbing and weaving lately. The redemption is slated for December 15, 2026, when the notes will get delisted from...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Kentucky Power's Bold Plan to Boost Local Economy

Electricity, Economy, and Execution Kentucky Power just laid out plans that could massively swing the pendulum for eastern Kentucky's economic prospects. They've put filings on the table for the Kentucky Public Service Commission that, if approved, promise big economic benefits. We're talking about a potential infusion of $500 million through fixed-rate offsets and an...

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

LaserAway Expands to 244 Clinics Over 20 Years

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....